TY - JOUR AU - Rossi, Rosanna AU - Douglas, Andrew AU - Gil, Sara Molina AU - Jabrah, Duaa AU - Pandit, Abhay AU - Gilvarry, Michael AU - McCarthy, Ray AU - Prendergast, James AU - Jood, Katarina AU - Redfors, Petra AU - Nordanstig, Annika AU - Ceder, Erik AU - Dunker, Dennis AU - Carlqvist, Jeanette AU - Szikora, István AU - Thornton, John AU - Tsivgoulis, Georgios AU - Psychogios, Klearchos AU - Tatlisumak, Turgut AU - Rentzos, Alexandros AU - Doyle, Karen M TI - S100b in acute ischemic stroke clots is a biomarker for post-thrombectomy intracranial hemorrhages. JF - FRONTIERS IN NEUROLOGY J2 - FRONT NEUR VL - 13 PY - 2023 SN - 1664-2295 DO - 10.3389/fneur.2022.1067215 UR - https://m2.mtmt.hu/api/publication/33636072 ID - 33636072 N1 - Department of Physiology and Galway Neuroscience Centre, School of Medicine, National University of Ireland, Galway, Ireland CÚRAM–SFI Research Centre in Medical Devices, National University of Ireland Galway, Galway, Ireland Galway, Cerenovus, Ireland Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden Department of Interventional and Diagnostic Neuroradiology, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden Department of Neurointerventions, National Institute of Clinical Neurosciences, Budapest, Hungary Department of Radiology, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland Second Department of Neurology, “Attikon” University Hospital, National and Kapodistrian University of Athens, Athens, Greece Stroke Unit, Metropolitan Hospital, Piraeus, Greece Cited By :3 Export Date: 7 November 2023 Correspondence Address: Rossi, R.; Department of Physiology and Galway Neuroscience Centre, Ireland; email: rosanna.rossi@nuigalway.ie Correspondence Address: Doyle, K.M.; Department of Physiology and Galway Neuroscience Centre, Ireland; email: karen.doyle@nuigalway.ie AB - Post-thrombectomy intracranial hemorrhages (PTIH) are dangerous complications of acute ischemic stroke (AIS) following mechanical thrombectomy. We aimed to investigate if S100b levels in AIS clots removed by mechanical thrombectomy correlated to increased risk of PTIH.We analyzed 122 thrombi from 80 AIS patients in the RESTORE Registry of AIS clots, selecting an equal number of patients having been pre-treated or not with rtPA (40 each group). Within each subgroup, 20 patients had developed PTIH and 20 patients showed no signs of hemorrhage. Gross photos of each clot were taken and extracted clot area (ECA) was measured using ImageJ. Immunohistochemistry for S100b was performed and Orbit Image Analysis was used for quantification. Immunofluorescence was performed to investigate co-localization between S100b and T-lymphocytes, neutrophils and macrophages. Chi-square or Kruskal-Wallis test were used for statistical analysis.PTIH was associated with higher S100b levels in clots (0.33 [0.08-0.85] vs. 0.07 [0.02-0.27] mm2, H1 = 6.021, P = 0.014*), but S100b levels were not significantly affected by acute thrombolytic treatment (P = 0.386). PTIH was also associated with patients having higher NIHSS at admission (20.0 [17.0-23.0] vs. 14.0 [10.5-19.0], H1 = 8.006, P = 0.005) and higher number of passes during thrombectomy (2 [1-4] vs. 1 [1-2.5], H1 = 5.995, P = 0.014*). S100b co-localized with neutrophils, macrophages and with T-lymphocytes in the clots.Higher S100b expression in AIS clots, higher NIHSS at admission and higher number of passes during thrombectomy are all associated with PTIH. Further investigation of S100b expression in AIS clots by neutrophils, macrophages and T-lymphocytes could provide insight into the role of S100b in thromboinflammation. LA - English DB - MTMT ER - TY - JOUR AU - Loevner, Laurie A AU - Kolumban, Balint AU - Hutóczki, Gábor AU - Dziadziuszko, Katarzyna AU - Bereczki, Dániel AU - Bagó, Attila György AU - Pichiecchio, Anna TI - Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System. The PICTURE Randomized Clinical Trial. TS - The PICTURE Randomized Clinical Trial. JF - INVESTIGATIVE RADIOLOGY J2 - INVEST RADIOL VL - 58 PY - 2023 IS - 5 SP - 307 EP - 313 PG - 7 SN - 0020-9996 DO - 10.1097/RLI.0000000000000944 UR - https://m2.mtmt.hu/api/publication/33623134 ID - 33623134 N1 - Department of Radiology, University of Pennsylvania, Philadelphia, PA, United States Department of Neurosurgery, University of Pécs, Pécs, Hungary Department of Neurosurgery, University of Debrecen, Debrecen, Hungary Department of Radiology Early Clinical Trials Centre, Medical University of Gdansk, Gdansk, Poland Department of Neurology, Semmelweis University, Hungary Department of Neuro-oncology, National Institute of Clinical Neurosciences, Budapest, Hungary Department of Brain and Behavioral Sciences, University of Pavia, Italy Department of Neuroradiology, IRCCS, Mondino Foundation, Pavia, Italy Cited By :4 Export Date: 3 October 2023 CODEN: INVRA Correspondence Address: Loevner, L.A.; Department of Radiology, 3400 Spruce St., United States; email: Laurie.Loevner@pennmedicine.upenn.edu AB - Developing new high relaxivity gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) allowing dose reduction while maintaining similar diagnostic efficacy is needed, especially in the context of gadolinium retention in tissues. This study aimed to demonstrate that contrast-enhanced MRI of the central nervous system (CNS) with gadopiclenol at 0.05 mmol/kg is not inferior to gadobutrol at 0.1 mmol/kg, and superior to unenhanced MRI.PICTURE is an international, randomized, double-blinded, controlled, cross-over, phase III study, conducted between June 2019 and September 2020. Adult patients with CNS lesions were randomized to undergo 2 MRIs (interval, 2-14 days) with gadopiclenol (0.05 mmol/kg) then gadobutrol (0.1 mmol/kg) or vice versa. The primary criterion was lesion visualization based on 3 parameters (border delineation, internal morphology, and contrast enhancement), assessed by 3 off-site blinded readers. Key secondary outcomes included lesion-to-background ratio, enhancement percentage, contrast-to-noise ratio, overall diagnostic preference, and adverse events.Of the 256 randomized patients, 250 received at least 1 GBCA administration (mean [SD] age, 57.2 [13.8] years; 53.6% women). The statistical noninferiority of gadopiclenol (0.05 mmol/kg) to gadobutrol (0.1 mmol/kg) was achieved for all parameters and all readers (n = 236, lower limit 95% confidence interval of the difference ≥-0.06, above the noninferiority margin [-0.35], P < 0.0001), as well as its statistical superiority over unenhanced images (n = 239, lower limit 95% confidence interval of the difference ≥1.29, P < 0.0001).Enhancement percentage and lesion-to-background ratio were higher with gadopiclenol for all readers (P < 0.0001), and contrast-to-noise ratio was higher for 2 readers (P = 0.02 and P < 0.0001). Three blinded readers preferred images with gadopiclenol for 44.8%, 54.4%, and 57.3% of evaluations, reported no preference for 40.7%, 21.6%, and 23.2%, and preferred images with gadobutrol for 14.5%, 24.1%, and 19.5% (P < 0.001).Adverse events reported after MRI were similar for gadopiclenol (14.6% of patients) and gadobutrol (17.6%). Adverse events considered related to gadopiclenol (4.9%) and gadobutrol (6.9%) were mainly injection site reactions, and none was serious.Gadopiclenol at 0.05 mmol/kg is not inferior to gadobutrol at 0.1 mmol/kg for MRI of the CNS, confirming that gadopiclenol can be used at half the gadolinium dose used for other GBCAs to achieve similar clinical efficacy. LA - English DB - MTMT ER - TY - JOUR AU - Woldmar, N AU - Schwendenwein, A AU - Kuras, M AU - Szeitz, Beáta AU - Boettiger, K AU - Sólyom-Tisza, Anna AU - Laszlo, Viktoria AU - Reiniger, Lilla AU - Bagó, Attila György AU - Szállási, Zoltán AU - Moldvay, Judit AU - Szász, Attila Marcell AU - Malm, J AU - Horvatovich, P AU - Pizzatti, L AU - Domont, G B AU - Rényi-Vámos, Ferenc István AU - Hoetzenecker, K AU - Hoda, M A AU - Marko-Varga, G AU - Schelch, K AU - Megyesfalvi, Zsolt AU - Rezeli, M AU - Döme, Balázs TI - Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases JF - ESMO OPEN J2 - ESMO OPEN VL - 8 PY - 2023 IS - 1 PG - 13 SN - 2059-7029 DO - 10.1016/j.esmoop.2022.100741 UR - https://m2.mtmt.hu/api/publication/33364842 ID - 33364842 AB - Background Brain metastases are associated with considerable negative effects on patients’ outcome in lung adenocarcinoma (LADC). Here, we investigated the proteomic landscape of primary LADCs and their corresponding brain metastases. Materials and methods Proteomic profiling was conducted on 20 surgically resected primary and brain metastatic LADC samples via label-free shotgun proteomics. After sample processing, peptides were analyzed using an Ultimate 3000 pump coupled to a QExactive HF-X mass spectrometer. Raw data were searched using PD 2.4. Further data analyses were carried out using Perseus, RStudio and GraphPad Prism. Proteomic data were correlated with clinical and histopathological parameters and the timing of brain metastases. Mass spectrometry-based proteomic data are available via ProteomeXchange with identifier PXD027259. Results Out of the 6821 proteins identified and quantified, 1496 proteins were differentially expressed between primary LADCs and corresponding brain metastases. Pathways associated with the immune system, cell-cell/matrix interactions and migration were predominantly activated in the primary tumors, whereas pathways related to metabolism, translation or vesicle formation were overrepresented in the metastatic tumors. When comparing fast- versus slow-progressing patients, we found 454 and 298 differentially expressed proteins in the primary tumors and brain metastases, respectively. Metabolic reprogramming and ribosomal activity were prominently up-regulated in the fast-progressing patients (versus slow-progressing individuals), whereas expression of cell-cell interaction- and immune system-related pathways was reduced in these patients and in those with multiple brain metastases. Conclusions This is the first comprehensive proteomic analysis of paired primary tumors and brain metastases of LADC patients. Our data suggest a malfunction of cellular attachment and an increase in ribosomal activity in LADC tissue, promoting brain metastasis. The current study provides insights into the biology of LADC brain metastases and, moreover, might contribute to the development of personalized follow-up strategies in LADC. LA - English DB - MTMT ER - TY - JOUR AU - Pierot, Laurent AU - Szikora, István AU - Barreau, Xavier AU - Holtmannspoetter, Markus AU - Spelle, Laurent AU - Klisch, Joachim AU - Herbreteau, Denis AU - Costalat, Vincent AU - Fiehler, Jens AU - Januel, Anne-Christine AU - Liebig, Thomas AU - Stockx, Luc AU - Weber, Werner AU - Berkefeld, Joachim AU - Moret, Jacques AU - Molyneux, Andy AU - Byrne, James TI - Aneurysm treatment with the Woven EndoBridge (WEB) device in the combined population of two prospective, multicenter series : 5-year follow-up JF - JOURNAL OF NEUROINTERVENTIONAL SURGERY J2 - J NEUROINTERV SURG VL - 15 PY - 2023 IS - 6 SP - 552 EP - 557 PG - 6 SN - 1759-8478 DO - 10.1136/neurintsurg-2021-018414 UR - https://m2.mtmt.hu/api/publication/32925428 ID - 32925428 N1 - Cited By :14 Export Date: 27 October 2023 Correspondence Address: Pierot, L.; Department of Neuroradiology, France; email: lpierot@gmail.com AB - Evaluating a new endovascular treatment for intracranial aneurysms must not only demonstrate short-term safety and efficacy, but also evaluate longer-term outcomes (eg, delayed complications, anatomical results, retreatment). The current analysis reports the 5-year clinical and anatomical results of Woven EndoBridge (WEB) treatment in two European combined trial populations (WEBCAST (WEB Clinical Assessment of Intrasaccular Aneurysm Therapy) and WEBCAST-2).All adverse events occurring between the procedure and 5-year follow-up were independently evaluated by an expert. Aneurysm occlusion was evaluated by an independent core laboratory using a three-grade scale: complete occlusion, neck remnant, and aneurysm remnant. In cases where data were not available at 5-year follow-up, the last observation carry forward (LOCF) method was used.The safety and efficacy populations comprised 100 patients and 95 aneurysms, respectively. No adverse event related to the device occurred after the procedure during the 5-year follow-up period. Mortality at 5 years was 7.0% (7/100 patients) including mortality related to the WEB (0/100, 0.0%), the procedure (1/100, 1.0%), and another condition (6/100, 6.0%). At 5 years, complete aneurysm occlusion was observed in 49/95 (51.6%) aneurysms, neck remnant in 25/95 (26.3%), and aneurysm remnant in 21/95 (22.1%). Retreatment rate at 5 years was 11.6% (11/95 aneurysms).This analysis conducted in a population of patients with wide-neck bifurcation aneurysms confirms WEB's safety profile. Additional evidence demonstrates good stability of aneurysm occlusion with adequate occlusion (complete occlusion or neck remnant) at 5 years in 77.9% of aneurysms with a low retreatment rate (11.6%).WEBCAST and WEBCAST-2: Unique identifier: NCT01778322. LA - English DB - MTMT ER - TY - JOUR AU - Hadady, Levente AU - Klivényi, Péter AU - Fabó, Dániel AU - Beniczky, Sándor TI - Real‐world user experience with seizure detection wearable devices in the home environment JF - EPILEPSIA J2 - EPILEPSIA VL - 64 PY - 2023 IS - Suppl 4 SP - S72 EP - S77 PG - 6 SN - 0013-9580 DO - 10.1111/epi.17189 UR - https://m2.mtmt.hu/api/publication/32720760 ID - 32720760 LA - English DB - MTMT ER - TY - JOUR AU - Szirmai, Danuta AU - Futó, Claudia AU - Frendl, Anita AU - Kis, Balázs AU - Kondor, Máté AU - Pozsár, Kinga AU - Kamondi, Anita TI - Központi idegrendszeri vasculitis gyanújával vizsgált betegek vizsgálati eredményeinek retrospektív feldolgozása (OKITI, 2016–2021) JF - IDEGGYÓGYÁSZATI SZEMLE PROCEEDINGS / CLINICAL NEUROSCIENCE PROCEEDINGS J2 - IDEGGYÓGY SZEMLE PROC VL - 7 PY - 2022 IS - 3 SP - 186 SN - 2498-6240 UR - https://m2.mtmt.hu/api/publication/33556642 ID - 33556642 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Ujma, Przemyslaw Péter AU - Dresler, Martin AU - Simor, Péter Dániel AU - Fabó, Dániel AU - Ulbert, István AU - Erőss, Loránd AU - Bódizs, Róbert TI - The sleep EEG envelope is a novel, neuronal firing-based human biomarker JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 12 PY - 2022 IS - 1 PG - 16 SN - 2045-2322 DO - 10.1038/s41598-022-22255-4 UR - https://m2.mtmt.hu/api/publication/33226625 ID - 33226625 N1 - Export Date: 16 May 2023 Correspondence Address: Ujma, P.P.; Institute of Behavioural Sciences, Hungary; email: ujma.peter@med.semmelweis-univ.hu Chemicals/CAS: Biomarkers Funding details: European Cooperation in Science and Technology, COST, CA18106 Funding details: Semmelweis Egyetem, TKP2021-EGA-25 Funding details: Nederlandse Organisatie voor Wetenschappelijk Onderzoek, NWO Funding details: Emberi Eroforrások Minisztériuma, EMMI Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFIH, 2017-1.2.1-NKP-2017-00002, K_128117, NKFIH-1157-8/2019-DT, NKFI_FK_128100 Funding text 1: This article is based upon work supported by the National Research, Development and Innovation Office of Hungary (Grants NKFI_FK_128100, K_128117, NKFIH-1157-8/2019-DT and 2017-1.2.1-NKP-2017-00002), the Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary within the framework of the Neurology thematic program of the Semmelweis University (TKP2021-EGA-25), a Vidi grant from the Netherlands Organisation for Scientific Research (NWO), and COST Action CA18106 supported by COST (European Cooperation in Science and Technology). AB - Sleep EEG reflects voltage differences relative to a reference, while its spectrum reflects its composition of various frequencies. In contrast, the envelope of the sleep EEG reflects the instantaneous amplitude of oscillations, while its spectrum reflects the rhythmicity of the occurrence of these oscillations. The sleep EEG spectrum is known to relate to demographic, psychological and clinical characteristics, but the envelope spectrum has been rarely studied. In study 1, we demonstrate in human invasive data from cortex-penetrating microelectrodes and subdural grids that the sleep EEG envelope spectrum reflects neuronal firing. In study 2, we demonstrate that the scalp EEG envelope spectrum is stable within individuals. A multivariate learning algorithm could predict age (r = 0.6) and sex (r = 0.5) from the EEG envelope spectrum. With age, oscillations shifted from a 4–5 s rhythm to faster rhythms. Our results demonstrate that the sleep envelope spectrum is a promising biomarker of demographic and disease-related phenotypes. LA - English DB - MTMT ER - TY - JOUR AU - Kelemen, Andrea Judit AU - Halász, László AU - Muthuraman, Muthuraman AU - Erőss, Loránd AU - Barsi, Péter AU - Zádori, Dénes AU - Laczó, Bence AU - Kis, Dávid AU - Klivényi, Péter AU - Fekete, Gábor AU - Bognár, László AU - Bereczki, Dániel AU - Tamás, Gertrúd TI - Clinical parameters predict the effect of bilateral subthalamic stimulation on dynamic balance parameters during gait in Parkinson's disease JF - FRONTIERS IN NEUROLOGY J2 - FRONT NEUR VL - 13 PY - 2022 PG - 9 SN - 1664-2295 DO - 10.3389/fneur.2022.917187 UR - https://m2.mtmt.hu/api/publication/33118864 ID - 33118864 AB - We investigated the effect of deep brain stimulation on dynamic balance during gait in Parkinson's disease with motion sensor measurements and predicted their values from disease-related factors. We recruited twenty patients with Parkinson's disease treated with bilateral subthalamic stimulation for at least 12 months and 24 healthy controls. Six monitors with three-dimensional gyroscopes and accelerometers were placed on the chest, the lumbar region, the two wrists, and the shins. Patients performed the instrumented Timed Up and Go test in stimulation OFF, stimulation ON, and right- and left-sided stimulation ON conditions. Gait parameters and dynamic balance parameters such as double support, peak turn velocity, and the trunk's range of motion and velocity in three dimensions were analyzed. Age, disease duration, the time elapsed after implantation, the Hoehn-Yahr stage before and after the operation, the levodopa, and stimulation responsiveness were reported. We individually calculated the distance values of stimulation locations from the subthalamic motor center in three dimensions. Sway values of static balance were collected. We compared the gait parameters in the OFF and stimulation ON states and controls. With cluster analysis and a machine-learning-based multiple regression method, we explored the predictive clinical factors for each dynamic balance parameter (with age as a confounder). The arm movements improved the most among gait parameters due to stimulation and the horizontal and sagittal trunk movements. Double support did not change after switching on the stimulation on the group level and did not differ from control values. Individual changes in double support and horizontal range of trunk motion due to stimulation could be predicted from the most disease-related factors and the severity of the disease; the latter also from the stimulation-related changes in the static balance parameters. Physiotherapy should focus on double support and horizontal trunk movements when treating patients with subthalamic deep brain stimulation. LA - English DB - MTMT ER - TY - JOUR AU - Parrino, Liborio AU - Halász, Péter AU - Szűcs, Anna AU - J Thomas, Robert AU - Azzi, Nicoletta AU - Rausa, Francesco AU - Pizzarotti, Silvia AU - Zilioli, Alessandro AU - Misirocchi, Francesco AU - Mutti, Carlotta TI - SLEEP MEDICINE: PRACTICE, CHALLENGES AND NEW FRONTIERS JF - FRONTIERS IN NEUROLOGY J2 - FRONT NEUR VL - 13 PY - 2022 PG - 41 SN - 1664-2295 DO - 10.3389/fneur.2022.966659 UR - https://m2.mtmt.hu/api/publication/33082116 ID - 33082116 N1 - Department of General and Specialized Medicine, Sleep Disorders Center, University Hospital of Parma, Parma, Italy Szentagothai János School of Ph.D Studies, Clinical Neurosciences, Semmelweis University, Budapest, Hungary Department of Behavioral Sciences, National Institute of Clinical Neurosciences, Semmelweis University, Budapest, Hungary Division of Pulmonary, Critical Care and Sleep, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States Department of Medicine and Surgery, Unit of Neurology, University of Parma, Parma, Italy Cited By :6 Export Date: 27 October 2023 Correspondence Address: Parrino, L.; Department of General and Specialized Medicine, Italy; email: liborio.parrino@unipr.it LA - English DB - MTMT ER - TY - JOUR AU - Szabó, Borbála AU - Németh, Kinga AU - Mészáros, Katalin AU - Krokker, Lilla AU - Likó, István AU - Saskői, Éva AU - Németh, Krisztina AU - Szabó, Pál Tamás AU - Szücs, Nikolette AU - Czirják, Sándor AU - Szalóki, Gábor AU - Patócs, Attila Balázs AU - Butz, Henriett TI - Aspirin mediates its antitumoral effect through inhibiting PTTG1 in pituitary adenoma JF - JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM J2 - J CLIN ENDOCR METAB VL - 107 PY - 2022 IS - 11 SP - 3066 EP - 3079 PG - 14 SN - 0021-972X DO - 10.1210/clinem/dgac496 UR - https://m2.mtmt.hu/api/publication/33081865 ID - 33081865 N1 - Department of Laboratory Medicine, Semmelweis University, Budapest, H-1089, Hungary Hereditary Tumours Research Group, Hungarian Academy of Sciences, Semmelweis University, Budapest, H-1089, Hungary Department of Molecular Genetics, National Tumor Biology Laboratory, National Institute of Oncology, Budapest, H-1122, Hungary MS Metabolomics Research Group, Centre for Structural Study, Research Centre for Natural Sciences, Eötvös Loránd Research Network, Budapest, H-1117, Hungary Department of Endocrinology, Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, Budapest, H-1083, Hungary National Institute of Clinical Neurosciences, Budapest, H-1145, Hungary Department of Pathology and Experimental Cancer Research, Faculty of Medicine, Semmelweis University, Budapest, H-1085, Hungary Cited By :2 Export Date: 29 July 2023 CODEN: JCEMA Correspondence Address: Butz, H.; Department of Laboratory Medicine, Hungary; email: butz.henriett@med.semmelweis-univ.hu Chemicals/CAS: 5 hydroxymethylcytosine, 1123-95-1; acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; decitabine, 2353-33-5; follitropin, 9002-68-0; gonadotropin, 63231-54-9; luteinizing hormone, 39341-83-8, 9002-67-9; testosterone, 58-22-0 Tradenames: Nanodrop2000, Thermo, United States; NovaSeq; QIAamp DNA Mini Manufacturers: Sigma, United StatesAgilent; Qiagen, Germany; Zymo Research, Hungary; Beckman Coulter, United States; Becton Dickinson, United States; Promega, United States; Thermo, United States AB - DNA demethylation and inhibitory effect of Aspirin on pituitary cell proliferation have been demonstrated.was to clarify the molecular mechanisms behind the Aspirin-related effects in pituitary cells.DNA methylome and whole transcriptome profile were investigated in RC4-B/C and GH3 pituitary cell lines upon Aspirin treatment. Effects of Aspirin and demethylation agent, decitabine, were further tested in vitro. PTTG1 expression in 41 human PitNET samples and whole genome gene and protein expression data of 76 PitNET and 34 control samples (available in Gene Expression Omnibus) were evaluated.Aspirin induced global DNA demethylation and consequential transcriptome changes. Overexpression of Tet enzymes and their cofactor Uhrf2 were identified behind the increase of 5-hydroxymethylcytosine (5hmC). Besides cell cycle, proliferation and migration that were validated by functional experiments, Aspirin increased Tp53 activity through p53 acetylation and decreased E2f1 activity. Among the p53 controlled genes, Pttg1 and its interacting partners were downregulated upon Aspirin treatment by inhibiting Pttg1 promoter activity. 5hmC positively correlated with Tet1-3, Tp53 expression, and negatively correlated with Pttg1 expression that was reinforced by the effect of decitabine. Additionally, high overlap (20.15%) was found between Aspirin regulated genes and dysregulated genes in PitNET tissue samples.A novel regulatory network has been revealed, where Aspirin regulated global demethylation, Tp53 activity and Pttg1 expression along with decreased cell proliferation and migration. 5hmC, a novel tissue biomarker in PitNET, indicated Aspirin antitumoral effect in vitro too. Our findings suggest the potential beneficial effect of Aspirin in PitNET. LA - English DB - MTMT ER -